Full Press Release Details
Ultragenyx Announces Sale of Future European Royalties on Crysvita (burosumab) for $320 Million to Royalty Pharma.
RARE
Ultragenyx Announces Sale of Future European Royalties on Crysvita (burosumab) for $320 Million to Royalty Pharma
Key Takeaway: Ultragenyx Announces Sale of Future European Royalties on Crysvita (burosumab) for $320 Million to Royalty Pharma